Skip to main content
AMRN logo

AMRN · Amarin Corp Plcuk · Documents

Track AMRN — free
$11.08 -0.18 (-1.60%) Play latest call Q3 2026 earnings call transcript
Market Cap
$473.40M
Shares
42.04M
Volume · Nov 20 47.19K Avg daily vol (3M) 76.61K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $213.65M down 6.5% 10-K filed Mar 2, 2026 Quarterly report FY2026 Q3 Revenue $39.55M down 20.4% 10-Q filed Oct 28, 2026 Latest results Third-quarter net income turns positive at $0.2 million 8-K filed Oct 28, 2026 Earnings call Q3 2026 earnings call Held Oct 28, 2026
2026
Nov 18
Current report 8-K Events of Nov 16
Director Patrice Bonfiglio resigns effective immediately, citing no disagreement

Patrice Bonfiglio notified Amarin Corporation plc on November 16, 2026 of her decision to resign as a director, effective immediately. The resignation is not the result of any disagreement with the Company on its operations, policies or practices.

Director or officer change, or executive pay
2 source passages
On November 16, 2026, Ms. Patrice Bonfiglio notified Amarin Corporation plc (the “Company”) of her decision to resign as a director of the Company, effective immediately. Ms. Bonfiglio’s decision to resign is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Open the document at this passage
Oct 28
Earnings call
Third-Quarter Revenue Falls to $39.6 Million; Net Income $245,000

Third-quarter 2026 net revenue was $39.6 million, down from $49.7 million a year earlier, and net income was $245,000. A colorectal cancer trial of the drug missed its primary progression-free survival endpoint but showed a 32% lower hazard of death in overall survival.

4 source passages
Total net revenue in the third quarter of 2026 was $39.6 million, compared to $49.7 million in the third quarter of 2025. net income for the quarter was $245,000, or less than $0.01 per share Importantly, while the primary endpoint of progression-free survival was not met, the study demonstrated an improvement in the key secondary endpoint of overall survival. A statistically significant 32% lower hazard of death, which is a meaningful finding in a patient population where up to 60% of patients may experience disease recurrence within two years following surgery. Open the document at this passage
Oct 28
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue falls 20% to $39.6 million on lower US sales

Amarin reported total revenue, net, of $39.6 million for the three months ended September 30, 2026, down $10.1 million, or 20%, from $49.7 million a year earlier. The decrease was due primarily to a $12.3 million decline in U.S. net product revenue. Gross margin on product sales fell to 37% from 43%, mainly due to a change in customer mix.

Revenue $39.55M ▼ 20.4% Net income $245K Diluted EPS $0.00
Read from the MD&A section
4 source passages
We recorded total revenue, net, of $39.6 million and $49.7 million during the three months ended September 30, 2026 and 2025, respectively, a decrease of $10.1 million, or 20%. As further discussed below, the aforementioned decrease was due primarily to a $12.3 million decrease in U.S. net product revenue Our overall gross margin on product sales for the three months ended September 30, 2026 and 2025 was 37% and 43%, respectively. The decrease in gross margin was primarily as a result of a change in customer mix. Open the document at this passage
Oct 28
Current report 8-K
Third-quarter net income turns positive at $0.2 million

Amarin reported third-quarter 2026 net income of $0.2 million, against a net loss of $(7.7) million a year earlier. Total net revenue fell 20% to $39.6 million. Cash and short-term investments reached $323.4 million, and the company remains debt-free.

Financial results
5 source passages
Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income Net Loss | $0.2 | $(7.7) | 103% Total Net Revenue | $39.6 | $49.7 | (20)% | $126.9 | $164.4 | (23)% Cash, Cash Equivalents & Short-Term Investments | $302.6 | $307.8 | $314.6 | $323.4 | ~$330 Our cash balance now exceeds $323 million and our balance sheet remains debt-free. Open the document at this passage
Jul 29
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $42.21M ▼ 42.0% Net loss $7.65M Diluted EPS -$0.02
Apr 29
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $45.13M ▲ 7.4% Net loss $10.51M Diluted EPS -$0.03
Mar 2
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $213.65M ▼ 6.5% Net loss $38.8M Diluted EPS -$0.09
2025
Mar 12
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $228.61M ▼ 25.5% Net loss $82.18M Diluted EPS -$0.20
2024
Showing 1–50 of 179 documents
Key facts CIK 897448 CUSIP 023111404 13F (30d) 87 filings 77 filers Visit website Investor relations